Destiny Pharma plc shares are now trading on JP Jenkins

JPJ: DESTINATION

ISIN code: GB00B60BD277

Destination Pharma plc

(“Destiny Pharma” or “the Company”)

Shares are now trading on JP Jenkins

London, UK, August 13, 2024 – Destiny Pharma plc (JPJ:DEST), a clinical-stage biotechnology company focused on the development and commercialization of novel medicines to prevent and cure life-threatening infections, today announces The company’s shares have been admitted to trading on the JP Jenkins stock trading platform. Destination Pharma plc is located at Unit 36 ​​​​Sussex Innovation Centre Science Park Square, Falmer, Brighton, BN1 9SB and is registered as a company in England and Wales under Companies House, company number 03167025.

About Destiny Pharma:

Destiny Pharma is an innovative clinical-stage biotechnology company focused on the development and commercialization of novel medicines to prevent life-threatening infections. The company’s drug development pipeline includes two late-stage assets: XF-73 Nasal Gel, a proprietary drug targeted at the prevention of hospital-acquired postoperative staphylococcal infections, including MRSA, and NTCD-M3, a microbiome-based biotherapeutic for the prevention of C. difficile infection (CDI) recurrence, the leading cause of hospital-acquired infections in the U.S.

JP Jenkins provides a trading platform for unlisted or unquoted assets in companies, allowing shareholders and potential investors to buy and sell shares on a matched bargain basis. JP Jenkins is a trading name of InfinitX Limited and an appointed representative of Prosper Capital LLP (FRN453007).

Shareholders wishing to trade these securities can do so through their stockbroker. Transactions will be executed at a level which JP Jenkins can match with a willing seller and a willing buyer. Transactions can be executed and limits accepted during normal business hours. Shareholders or potential investors can place limits through their existing UK regulated stockbroker.

The indicative pricing for the Ordinary Shares (ISIN: GB00BDHSP575), as well as the transaction history, will be available on the JP Jenkins website at https://jpjenkins.com/company/destiny-pharma/.

Veronika Oswald, Commercial Director of JP Jenkins said: “We are delighted to welcome another company from the pharmaceutical sector to JP Jenkins and are excited to support Destiny Pharma in their transition and growth as a private company.”

For further information please contact:

Distribution of CORPORATE NEWS, broadcast by EQS Group.
The publisher is solely responsible for the content of this communication.

End of announcement – EQS News Service

1966261 13-08-2024

Diskutieren Sie über die entaltenen Werte